NCT06474468View on ClinicalTrials.gov

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Advanced or Metastatic Esophageal Cancer
Interventions
DRUG

SHR-A2102；Adebrelimab；Cisplatin

"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."

Trial Locations (1)

250117

RECRUITING

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY